RxDoctor Payments Data

Larry Richmond, MD

Obstetrics & Gynecology · Anniston, ALNPI 1023091436

Payments from drug & device makers

$4,439in general payments, 2019–2025

Across 141 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$750
  • AbbVie$731
  • Sumitomo Pharma America, Inc.$230
  • Pfizer$224
  • Mayne Pharma Commercial LLC$156
  • plus $1K from 27 others

What the payments were for

  • Travel & lodging$87720%
  • Food & beverage$3,04369%
  • Education$50211%
  • Gifts$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,439 in reported general payments places this provider in the 80th percentile of 537 obstetrics & gynecology providers in Alabama.

See all obstetrics & gynecology providers in Alabama

Medicare billing

Part B allowed, 2024
$26,491
Medicare patients
100
Services billed
237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ElmironPentosan Polysulfate Sodium34$40,133
MyrbetriqMirabegron56$30,289
PremarinEstrogens, Conjugated84$22,906
GemtesaVibegron16$17,305
MounjaroTirzepatide15$15,609
Estradiol347$7,817
Tolterodine Tartrate ErTolterodine Tartrate15$4,239
Estradiol (Twice Weekly)Estradiol27$2,784
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet28$2,558
Solifenacin Succinate35$1,977
Norethindrone Acetate43$1,826
Ibandronate Sodium34$1,613
ValacyclovirValacyclovir Hcl28$1,571
Oxybutynin Chloride ErOxybutynin Chloride82$1,527
Spironolactone33$1,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$750$30,28956 claims
PfizerPremarin$224$22,90684 claims
Sumitomo Pharma America, Inc.Gemtesa$230$17,30516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 537 obstetrics & gynecology providers in Alabama.

Other obstetrics & gynecology in Anniston

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →